Literature DB >> 10731554

Serum müllerian-inhibiting substance levels during normal menstrual cycles.

C L Cook1, Y Siow, S Taylor, M E Fallat.   

Abstract

OBJECTIVE: To measure serum levels of müllerian-inhibiting substance (MIS) during the normal menstrual cycle.
DESIGN: Serum was collected from women during ovulation and the mid-luteal and early follicular phases of the menstrual cycles. It was stored frozen at -80 degrees C until assayed.
SETTING: University of Louisville Departments of Obstetrics and Gynecology and Surgery. PATIENT(S): Twenty healthy women 22-35 years of age with normal menstrual cycles. INTERVENTION(S): Blood samples were collected on menstrual cycle day two or three and on the day of LH surge plus one and plus seven or eight. MAIN OUTCOME MEASURE(S): Serum MIS levels were measured by using an enzyme-linked immunosorbent assay. RESULT(S): Serum MIS levels ranged from a low of 1.4 +/- 0.9 ng/mL (mean [+/-SD]) in the early follicular phase, peaked mid-cycle at 1.7 +/- 1.1 ng/mL, and decreased to 1.4 +/- 0.9 ng/mL in the mid-luteal phase of the normal menstrual cycle. CONCLUSION(S): Fluctuations in serum MIS levels during the menstrual cycle suggest that MIS may have a regulatory role in folliculogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731554     DOI: 10.1016/s0015-0282(99)00639-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  42 in total

1.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

2.  Differential Rates of Change in Measures of Ovarian Reserve in Young Cancer Survivors Across the Reproductive Lifespan.

Authors:  Katherine Cameron; Mary D Sammel; Maureen Prewitt; Clarisa Gracia
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

3.  Anti-Mullerian hormone normogram in an Irish subfertile population.

Authors:  M N Naasan; C Harrity; L Pentony; E Mocanu
Journal:  Ir J Med Sci       Date:  2014-02-23       Impact factor: 1.568

4.  "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population.

Authors:  Neeta Singh; Ekta Malik; Ayan Banerjee; Kunzang Chosdol; V Sreenivas; Suneeta Mittal
Journal:  J Obstet Gynaecol India       Date:  2013-02-22

5.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

6.  Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Authors:  MaryFran Sowers; Daniel McConnell; Katherine Gast; Huiyong Zheng; Bin Nan; Jenifer D McCarthy; John F Randolph
Journal:  Fertil Steril       Date:  2009-12-06       Impact factor: 7.329

7.  Serum antimüllerian hormone predicts ovarian reserve in a monkey model.

Authors:  Susan E Appt; Thomas B Clarkson; Haiying Chen; Michael R Adams; Patricia J Christian; Patricia B Hoyer; Mark E Wilson; Jay R Kaplan
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

Review 8.  Hormone changes associated with the menopausal transition.

Authors:  H I Su; E W Freeman
Journal:  Minerva Ginecol       Date:  2009-12

9.  Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.

Authors:  Henry L Chang; Nima Pahlavan; Elkan F Halpern; David T MacLaughlin
Journal:  Gynecol Oncol       Date:  2009-04-08       Impact factor: 5.482

10.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.